Imperial College London
Portrait Picture

Simon Erridge

Faculty of Medicine, Department of Surgery & Cancer

Research Postgraduate
 
 
 
//

Contact

 

simon.erridge12

 
 
//

Location

 

Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ergisi:2022:10.1080/17512433.2022.2020640,
author = {Ergisi, M and Erridge, S and Harris, M and Kawka, M and Nimalan, D and Salazar, O and Loupasaki, K and Ali, R and Holvey, C and Coomber, R and Platt, M and Rucker, JJ and Sodergren, MH},
doi = {10.1080/17512433.2022.2020640},
journal = {Expert Review of Clinical Pharmacology},
pages = {487--495},
title = {UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder},
url = {http://dx.doi.org/10.1080/17512433.2022.2020640},
volume = {15},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - ObjectivesAnxiety disorders are one of the most common reasons for seeking treatment with cannabis-based medicinal products (CBMPs). Current pharmacological treatments are variable in efficacy and the endocannabinoid system has been identified as a potential therapeutic target. This study aims to detail the changes in health-related quality-of-life (HRQoL) and clinical safety following CBMP therapy for generalized anxiety disorder.MethodsA case series from the UK Medical Cannabis Registry was performed. Primary outcomes included changes from baseline in patient-reported outcome measures (the General Anxiety Disorder Scale (GAD-7), EQ-5D-5L (a measure of health-related quality of life), and Sleep Quality Scale (SQS)) at 1, 3 and 6 months. Statistical significance was defined as p<0.050.ResultsSixty-seven patients were treated for generalized anxiety disorder. Statistically significant improvements were observed in GAD-7, EQ-5D-5L Index Value, EQ5D Visual Analog Scale, and SQS scores at 1, 3 and 6 months (p<0.050). Twenty-five (39.1%) patients reported adverse events during the follow-up period.ConclusionThis study suggests that CBMPs may be associated with improvements in HRQoL outcomes when used as a treatment for generalized anxiety disorder. These findings must be treated with caution considering limitations of study design; however this data may help inform future clinical studies and practice.
AU  - Ergisi,M
AU  - Erridge,S
AU  - Harris,M
AU  - Kawka,M
AU  - Nimalan,D
AU  - Salazar,O
AU  - Loupasaki,K
AU  - Ali,R
AU  - Holvey,C
AU  - Coomber,R
AU  - Platt,M
AU  - Rucker,JJ
AU  - Sodergren,MH
DO  - 10.1080/17512433.2022.2020640
EP  - 495
PY  - 2022///
SN  - 1751-2433
SP  - 487
TI  - UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder
T2  - Expert Review of Clinical Pharmacology
UR  - http://dx.doi.org/10.1080/17512433.2022.2020640
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000743810300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.tandfonline.com/doi/full/10.1080/17512433.2022.2020640
UR  - http://hdl.handle.net/10044/1/103471
VL  - 15
ER  -
Download